Table 1 Demographic and clinical characteristics of colorectal cancer cases according to TIMP1 serum levels and histoscore values in tumor cells and other cells in tumor tissue.
From: Associations of serum and tissue TIMP1 with host response and survival in colorectal cancer
Characteristic | TIMP1 histoscore in tumors | TIMP1 serum | ||||||
|---|---|---|---|---|---|---|---|---|
Total N | TIMP1 tumor cells Median (IQR) | P | TIMP1 stromal cells Median (IQR) | P | Total N | TIMP1 serum ng/ml Median (IQR) | P | |
All cases | 757 (100%) | 111 (66–156) | 81 (53–110) | 606 (100%) | 317 (268–376) | |||
Sex | 0.62 | 0.69 | 0.15 | |||||
Male | 401 (53%) | 106 (67–155) | 82 (54–106) | 330 (54%) | 312 (262–376) | |||
Female | 356 (47%) | 112 (66–158) | 80 (52–114) | 276 (46%) | 322 (276–377) | |||
Age (years) | 0.63 | 0.93 | < 0.001 | |||||
< 65 | 228 (30%) | 111 (66–159) | 81 (52–114) | 175 (29%) | 292 (252–360) | |||
65–75 | 279 (37%) | 111 (71–158) | 81 (55–111) | 226 (37%) | 320 (275–380) | |||
> 75 | 250 (33%) | 109 (60–153) | 81 (53–107) | 205 (34%) | 333 (273–397) | |||
ASA classification | 0.38 | 0.499 | < 0.001 | |||||
1 | 39 (5%) | 117 (80–166) | 77 (52–109) | 32 (5%) | 282 (241–330) | |||
2 | 287 (38%) | 111 (71–156) | 84 (57–119) | 242 (40%) | 313 (263–369) | |||
3 | 312 (41%) | 110 (72–157) | 83 (54–108) | 252 (41%) | 316 (269–375) | |||
4 | 61 (8%) | 130 (75–172) | 84 (62–110) | 51 (9%) | 372 (304–444) | |||
Missing data | 58 (8%) | 29 (5%) | ||||||
Tumor location | < 0.001 | < 0.001 | 0.032 | |||||
Proximal colon | 315 (42%) | 125 (74–170) | 91 (63–126) | 252 (42%) | 330 (276–380) | |||
Distal colon | 204 (27%) | 98 (54–145) | 70 (48–98) | 165 (27%) | 317 (272–382) | |||
Rectum | 238 (31%) | 106 (72–147) | 76 (50–101) | 189 (31%) | 302 (259–358) | |||
AJCC disease stage | 0.49 | 0.047 | 0.12 | |||||
I | 174 (23%) | 104 (59–152) | 84 (57–111) | 156 (26%) | 310 (261–372) | |||
II | 251 (33%) | 114 (72–163) | 84 (56–111) | 188 (31%) | 317 (272–376) | |||
III | 248 (33%) | 108 (66–159) | 79 (53–113) | 204 (34%) | 313 (270–366) | |||
IV | 84 (11%) | 113 (58–154) | 67 (45–100) | 58 (9%) | 350 (273–434) | |||
Tumor grade | 0.027 | 0.011 | 0.054 | |||||
Low-grade | 651 (86%) | 106 (66–152) | 80 (53–107) | 518 (85%) | 313 (265–376) | |||
High-grade | 106 (14%) | 126 (71–171) | 86 (57–130) | 88 (15%) | 334 (284–396) | |||
Lymphovascular invasion | 0.28 | 0.024 | 0.83 | |||||
No | 413 (55%) | 112 (68–157) | 84 (57–113) | 338 (56%) | 313 (270–377) | |||
Yes | 344 (45%) | 108 (65–154) | 77 (49–107) | 268 (44%) | 320 (259–375) | |||
MMR status | < 0.001 | < 0.001 | < 0.001 | |||||
MMR proficient | 639 (84%) | 105 (61–149) | 77 (51–104) | 509 (84%) | 311 (263–372) | |||
MMR deficient | 118 (16%) | 152 (94–185) | 109 (78–138) | 97 (16%) | 346 (294–401) | |||
BRAF status | < 0.001 | < 0.001 | 0.0064 | |||||
Wild-type | 651 (86%) | 104 (60–146) | 77 (51–104) | 513 (85%) | 312 (266–372) | |||
Mutant | 106 (14%) | 158 (124–207) | 115 (86–136) | 87 (14%) | 342 (293–400) | |||
Missing data | 6 (1%) | |||||||
mGPS | < 0.001 | 0.009 | < 0.001 | |||||
0 | 554 (73%) | 106 (60–151) | 79 (52–107) | 469 (77%) | 303 (256–354) | |||
1 | 96 (13%) | 106 (71–182) | 78 (50–109) | 77 (13%) | 377 (302–427) | |||
2 | 53 (7%) | 146 (105–173) | 95 (67–126) | 51 (9%) | 387 (333–474) | |||
Missing data | 54 (7%) | 9 (1%) | ||||||
